Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc.
Your view on COCP
Overview
What the company does, where it operates, and who runs it.
About Cocrystal Pharma, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Sam Lee
- Headquarters
- 19805 North Creek Parkway, Bothell, WA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Sam Lee
- Headquarters
- 19805 North Creek Parkway, Bothell, WA, US
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections.
The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection.
It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Cocrystal Pharma, Inc., and the rating behind it. COCP last traded at $1.24; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Cocrystal Pharma, Inc.. Starting points for Cocrystal Pharma, Inc.: EPS -$0.72, beta 1.48 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Cocrystal Pharma, Inc.. Cocrystal Pharma, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Cocrystal Pharma, Inc.. Trailing twelve-month EPS for Cocrystal Pharma, Inc. stands at -$0.72. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Cocrystal Pharma, Inc.. Cocrystal Pharma, Inc. has reported as a listed company since 2012. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Cocrystal Pharma, Inc. valued side by side against its closest peers. Cocrystal Pharma, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Cocrystal Pharma, Inc., and how their positions are changing. At a $17.1M market value, institutional positions materially move Cocrystal Pharma, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Cocrystal Pharma, Inc. executives and directors. Shares of Cocrystal Pharma, Inc. have traded between $0.98 and $3.26 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Cocrystal Pharma, Inc.. Cocrystal Pharma, Inc. is a $17.1M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Cocrystal Pharma, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Cocrystal Pharma, Inc.. Coverage tracks Cocrystal Pharma, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.